We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
From May 2019 to May 2024
By Stephen Nakrosis
The Janssen Pharmaceutical Cos. of Johnson & Johnson (JNJ) said Thursday the U.S. Food and Drug Administration had granted breakthrough therapy designation for Niraparib, a treatment for certain prostate cancer patients.
The company said the designation was based on data from its Galahad study, which is evaluating Niraparib as a treatment for certain patients with metastatic castration-resistant prostate cancer.
The company is also studying Niraparib in combination for the treatment of metastatic prostate cancer.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 03, 2019 17:28 ET (21:28 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
